Dr. Ansgar Santel leads Pantherna Therapeutics as CEO. He joined in 2021 to head translational research and partnerships, driving PAN004's early development. With a background in RNA therapeutics from Silence Therapeutics and Ascenion, he possesses a deep understanding of the biotech business landscape. Ansgar holds a PhD from Philipps-Universität Marburg and conducted postdoctoral research at Stanford University. He is a recognized researcher with significant publications and patents